Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Journal of General Internal Medicine
Erschienen in: Journal of General Internal Medicine 9/2013

01.09.2013 | Reviews

Preventive Pharmacologic Treatments for Episodic Migraine in Adults

verfasst von: Tatyana A. Shamliyan, MD, MS, Jae-Young Choi, PhD, Rema Ramakrishnan, MPH, Jennifer Biggs Miller, PT, MPH, Shi-Yi Wang, MD, PhD, Frederick R. Taylor, MD, Robert L. Kane, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

OBJECTIVES

Systematic review of preventive pharmacologic treatments for community-dwelling adults with episodic migraine.

DATA SOURCES

Electronic databases through May 20, 2012.

ELIGIBILITY CRITERIA

English-language randomized controlled trials (RCTs) of preventive drugs compared to placebo or active treatments examining rates of ≥50 % reduction in monthly migraine frequency or improvement in quality of life.

STUDY APPRAISAL AND SYNTHESIS METHODS

We assessed risk of bias and strength of evidence and conducted random effects meta-analyses of absolute risk differences and Bayesian network meta-analysis.

RESULTS

Of 5,244 retrieved references, 215 publications of RCTs provided mostly low-strength evidence because of the risk of bias and imprecision. RCTs examined 59 drugs from 14 drug classes. All approved drugs, including topiramate (9 RCTs), divalproex (3 RCTs), timolol (3 RCTs), and propranolol (4 RCTs); off-label beta blockers metoprolol (4 RCTs), atenolol (1 RCT), nadolol (1 RCT), and acebutolol (1 RCT); angiotensin-converting enzyme inhibitors captopril (1 RCT) and lisinopril (1 RCT); and angiotensin II receptor blocker candesartan (1 RCT), outperformed placebo in reducing monthly migraine frequency by ≥50 % in 200–400 patients per 1,000 treated. Adverse effects leading to treatment discontinuation (68 RCTs) were greater with topiramate, off-label antiepileptics, and antidepressants than with placebo. Limited direct evidence as well as frequentist and exploratory network Bayesian meta-analysis showed no statistically significant differences in benefits between approved drugs. Off-label angiotensin-inhibiting drugs and beta-blockers were most effective and tolerable for episodic migraine prevention.

LIMITATIONS

We did not quantify reporting bias or contact principal investigators regarding unpublished trials.

CONCLUSIONS

Approved drugs prevented episodic migraine frequency by ≥50 % with no statistically significant difference between them. Exploratory network meta-analysis suggested that off-label angiotensin-inhibiting drugs and beta-blockers had favorable benefit-to-harm ratios. Evidence is lacking for long-term effects of drug treatments (i.e., trials of more than 3 months duration), especially for quality of life.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Goadsby PJ, Raskin NH. Chapter 15. Headache. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison’s principles of internal medicine. 17th ed. New York: The McGraw-Hill Companies; 2008.
2.
3.
Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000;55:S29–35.PubMedCrossRef
4.
Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47:355–63.PubMed
5.
Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885–94.PubMedCrossRef
6.
Bigal ME, Lipton RB, Winner P, et al. Migraine in adolescents: association with socioeconomic status and family history. Neurology. 2007;69:16–25.PubMedCrossRef
7.
Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia. 2000;20:573–9.PubMedCrossRef
8.
Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl 1):9–160.
9.
Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–6.PubMedCrossRef
10.
Solomon S. New appendix criteria open for a broader concept of chronic migraine (Comment on: Cephalagia 2006 Jun:26(6):742–6). Cephalalgia. 2007;27:469. author reply −70.PubMedCrossRef
11.
Stewart WF, Ricci JA, Chee E, Morganstein D. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med. 2003;45:1234–46.PubMedCrossRef
12.
Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159:813–8.PubMedCrossRef
13.
Burton WN, Landy SH, Downs KE, Runken MC. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009;84:436–45.PubMed
14.
Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60:441–8.PubMedCrossRef
15.
16.
Rapoport AM. Acute and prophylactic treatments for migraine: present and future. Neurol Sci. 2008;29(Suppl 1):S110–22.PubMedCrossRef
17.
Stafford RS. Regulating off-label drug use–rethinking the role of the FDA. N Engl J Med. 2008;358:1427–9.PubMedCrossRef
18.
Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484–95.PubMedCrossRef
19.
Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician. 2003;67(1392):5–7.
20.
Morey SS. Guidelines on migraine: part 4. General principles of preventive therapy. Am Fam Physician. 2000;62:2359–60.PubMed
21.
Lainez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007;14:900–6.PubMedCrossRef
22.
Luykx J, Mason M, Ferrari MD, Carpay J. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85:283–8.PubMedCrossRef
23.
Geraud G, Lanteri-Minet M, Lucas C, Valade D. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004;26:1305–18.PubMedCrossRef
24.
Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine–revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.PubMedCrossRef
25.
Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. New guidelines for the management of migraine in primary care. Curr Med Res Opin. 2002;18:414–39.PubMedCrossRef
26.
Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA. 2004;291:2359–66.PubMedCrossRef
27.
Amanzio M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain. 2009;146:261–9.PubMedCrossRef
28.
Whyte CA, Tepper SJ. Adverse effects of medications commonly used in the treatment of migraine. Expert Rev Neurother. 2009;9:1379–91.PubMedCrossRef
29.
Sung NS, Crowley WF Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA. 2003;289:1278–87.PubMedCrossRef
30.
Institute of Medicine (US). Finding what works in health care: Standards for systematic reviews. Heidelberg: National Academies Press; 2011.
31.
Institute of Medicine (US). Committee on Ethical and Scientific Issues in Studying the Safety of Approved Drugs. Ethical and scientific issues in studying the safety of approved drugs. Washington: National Academies Press; 2012.
32.
33.
Helfand M, Balshem H. Principles in Developing and Applying Guidance. 2008.
34.
Whitlock EP, Lopez SA, Chang S, Helfand M, Eder M, Floyd N. AHRQ series paper 3: identifying, selecting, and refining topics for comparative effectiveness systematic reviews: AHRQ and the effective health-care program. J Clin Epidemiol. 2010;63:491–501.PubMedCrossRef
35.
Rothner AD. Complicated migraine and migraine variants. Curr Pain Headache Rep. 2002;6:233–9.PubMedCrossRef
36.
Hansen JM, Thomsen LL, Olesen J, Ashina M. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology. 2008;71:841–7.PubMedCrossRef
37.
38.
Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program. J Clin Epidemiol. 2008;63:502–12.PubMedCrossRef
39.
Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. London: The Cochrane Collaboration; 2011.
40.
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedCrossRef
41.
van der Velde G, van Tulder M, Cote P, et al. The sensitivity of review results to methods used to appraise and incorporate trial quality into data synthesis. Spine. 2007;32:796–806. Phila Pa 1976.PubMedCrossRef
42.
Herbison P, Hay-Smith J, Gillespie WJ. Adjustment of meta-analyses on the basis of quality scores should be abandoned. J Clin Epidemiol. 2006;59:1249–56.PubMedCrossRef
43.
Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009;9:80.PubMedCrossRef
44.
Egger M, Smith GD, Altman DG. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Books; 2001.CrossRef
45.
Treadwell JR, Uhl S, Tipton K, et al. Assessing equivalence and noninferiority. J Clin Epidemiol. 2012;65:1144–9.PubMedCrossRef
46.
Lievre M, Cucherat M, Leizorovicz A. Pooling, meta-analysis, and the evaluation of drug safety. Current controlled trials in cardiovascular medicine. 2002;3:6.PubMedCrossRef
47.
48.
Rucker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med. 2009;28:721–38.PubMedCrossRef
49.
Bradburn MJ, Deeks JJ, Berlin JA, Russell LA. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.PubMedCrossRef
50.
Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–75.PubMedCrossRef
51.
Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. Stat Med. 2010;29:3046–67.PubMedCrossRef
52.
White IR. Multivariate random-effects meta-regression: Updates to mvmeta. The Stata Journal 2011;11.
53.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health-Care Program. J Clin Epidemiol. 2010;63:513–23.PubMedCrossRef
54.
Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat Med. 2007;26:37–52.PubMedCrossRef
55.
Knapp G, Biggerstaff BJ, Hartung J. Assessing the amount of heterogeneity in random-effects meta-analysis. Biom J. 2006;48:271–85.PubMedCrossRef
56.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef
57.
Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA. 1962;179:717–8.CrossRef
58.
Ebrahim S. The use of numbers needed to treat derived from systematic reviews and meta-analysis. Caveats and pitfalls. Eval Health Prof. 2001;24:152–64.PubMedCrossRef
59.
60.
Coory M, Jordan S. Frequency of treatment-effect modification affecting indirect comparisons: a systematic review. Pharmcoeconomics. 2010;28:723–32.CrossRef
61.
Wells G, Sultan S, Chen L, Khan M, Coyle D. Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
62.
Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9:1–134. iii-iv.PubMed
63.
Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:b1147.PubMedCrossRef
64.
Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One. 2010;5:e11054.PubMedCrossRef
65.
Carlin BP, Louis TA. Bayesian methods for data analysis. Boca Raton: Chapman & Hall/CRC; 2009.
66.
Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Research Synthesis Methods. 2012;3:98–110.CrossRef
67.
Aschengrau A, Seage GR. Essentials of epidemiology in public health. Sudbury: Jones and Bartlett; 2003.
68.
Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS- a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing. 2000;10:325–37.CrossRef
69.
Berkman ND, Lohr KN, Morgan LC, et al. Reliability Testing of the AHRQ EPC Approach to Grading the Strength of Evidence in Comparative Effectiveness Reviews. Rockville (MD) 2012.
70.
Guyatt G, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011.
71.
Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.PubMedCrossRef
72.
Silberstein S. Efficacy and safety of topiramate in migraine prevention: a dose-ranging, placebo-controlled, double-blind, multicenter study. Advanced Studies in Medicine. 2003;3:S565–8.
73.
Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–73.PubMedCrossRef
74.
Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490–5.PubMedCrossRef
75.
Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007;6:1054–62.PubMedCrossRef
76.
Brandes JL, Kudrow DB, Rothrock JF, Rupnow MF, Fairclough DL, Greenberg SJ. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc. 2006;81:1311–9.PubMedCrossRef
77.
Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.PubMedCrossRef
78.
Dahlof C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes. 2007;5:56.PubMedCrossRef
79.
Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103–8.PubMedCrossRef
80.
Mei D, Ferraro D, Zelano G, et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol. 2006;29:269–75.PubMedCrossRef
81.
Lipton RB, Silberstein S, Dodick D, et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011;31:18–30.PubMedCrossRef
82.
Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract. 2005;59:961–8.PubMedCrossRef
83.
Forssman B, Henriksson KG, Johannsson V, et al. Propranolol for migraine prophylaxis. Headache. 1976;16(5):238–45.PubMedCrossRef
84.
Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well tolerated? Headache. 2002;42:235.PubMed
85.
Nanda RN, Johnson RH, Gray J, Keogh HJ, Melville ID. A double blind trial of acebutolol for migraine prophylaxis. Headache. 1978;18(1):20–2.PubMedCrossRef
86.
Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache. 1983;23(4):188–90.PubMedCrossRef
87.
Freitag FG, Diamond S. Nadolol and placebo comparison study in the prophylactic treatment of migraine. The Journal of the American Osteopathic Association. 1984;84(4):343–7.PubMed
88.
Minervini MG, Pinto K. Captopril relieves pain and improves mood depression in depressed patients with classical migraine. Cephalalgia. 1987;7(Suppl 6):485–6.
89.
Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ. 2001;322:19–22.PubMedCrossRef
90.
Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65–9.PubMedCrossRef
91.
Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia. 2009;29:921–7.PubMedCrossRef
92.
Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9:175–85.PubMedCrossRef
93.
94.
Lampl C, Huber G, Adl J, et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol. 2009;16:943–8.PubMedCrossRef
95.
Silberstein SD, Hulihan J, Karim MR, et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006;28:1002–11.PubMedCrossRef
96.
Reuter U, Del Rio MS, Diener HC, et al. Migraines with and without aura and their response to preventive therapy with topiramate. Cephalalgia: an International Journal of Headache. 2010;30(5):543–51.
97.
Barden J, Derry S, McQuay HJ, Moore RA. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain. 2006;121:207–18.PubMedCrossRef
98.
Fox AW. Disease modification in migraine: study design and sample size implications. Headache. 2008;48:1169–75.PubMedCrossRef
99.
Hazard E, Munakata J, Bigal ME, Rupnow MFT, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health. 2009;12:55–64.PubMedCrossRef
100.
Russell MB, Hilden J, Sorensen SA, Olesen J. Familial occurrence of migraine without aura and migraine with aura. Neurology. 1993;43:1369–73.PubMedCrossRef
101.
Arends LR, Hoes AW, Lubsen J, Grobbee DE, Stijnen T. Baseline risk as predictor of treatment benefit: three clinical = meta-re-analyses. Stat Med. 2000;19:3497–518.PubMedCrossRef
102.
Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. Journal of Headache & Pain. 2010;11:151–6.CrossRef
103.
Schurks M, Zee RY, Buring JE, Kurth T. ACE D/I polymorphism, migraine, and cardiovascular disease in women. Neurology. 2009;72:650–6.PubMedCrossRef
104.
Feldman HL. Pushing drugs: genomics and genetics, the pharmaceutical industry, and the law of negligence. Washburn Law J. 2003;42:575–99.PubMed
105.
Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol. 2012;11:803–13.PubMedCrossRef
106.
Coebergh JA, Waldinger MD. Reversible anorgasmia with topiramate for migraine prophylaxis. The Journal of Neuropsychiatry and Clinical Neurosciences. 2012;24:E30–1.PubMed
107.
Huang CY, Keller JJ, Sheu JJ, Lin HC. Migraine and erectile dysfunction: evidence from a population-based case–control study. Cephalalgia. 2012;32:366–72.PubMedCrossRef
108.
Bingham MF, Johnson FR, Miller D. Modeling choice behavior for new pharmaceutical products. Value in Health. 2001;4:32–44.PubMedCrossRef
109.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.PubMedCrossRef
110.
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308–11.PubMedCrossRef
111.
Mullan RJ, Flynn DN, Carlberg B, et al. Systematic reviewers commonly contact study authors but do so with limited rigor. J Clin Epidemiol. 2009;62:138–42.PubMedCrossRef
112.
113.
114.
Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34:e1–9.PubMedCrossRef
115.
Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281–6.PubMedCrossRef
116.
Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652–9.PubMedCrossRef
117.
Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001;41:968–75.PubMedCrossRef
118.
Mei D, Capuano A, Vollono C, et al. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci. 2004;25:245–50.PubMedCrossRef
119.
Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003;23:820–4.PubMedCrossRef
120.
Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007;47:402–12.PubMed
121.
Silberstein S, Lipton R, Dodick D, et al. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009;49:1153–62.PubMedCrossRef
122.
Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand. 1984;69:1–8.PubMedCrossRef
123.
Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–50.PubMedCrossRef
124.
Diamond S, Medina JL. Double blind study of propranolol for migraine prophylaxis. Headache. 1976;16:24–7.PubMedCrossRef
125.
Standnes B. The prophylactic effect of timolol versus propranolol and placebo in common migraine: beta-blockers in migraine. Cephalalgia. 1982;2:165–70.PubMedCrossRef
126.
Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA. 1984;252:2576–80.PubMedCrossRef
127.
Wessely P, Baumgartner C, Klingler D, et al. Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia. 1987;7:477–8.
128.
Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119–28.PubMedCrossRef
129.
NCT00742209. Prevention study in adult patients suffering from migraine headaches. 2010.
130.
Havanka-Kanniainen H, Hokkanen E, Myllylä VV. Efficacy of nimodipine in the prophylaxis of migraine. Cephalalgia: an International Journal of Headache. 1985;5(1):39–43.CrossRef
131.
Gelmers HJ. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache. 1983;23(3):106–9.PubMedCrossRef
132.
Kangasniemi P, Andersen AR, Andersson PG, et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia. 1987;7:231–8.PubMedCrossRef
133.
Andersson PG, Dahl S, Hansen JH, et al. Prophylactic treatment of classical and non-classical migraine with metoprolol–a comparison with placebo. Cephalalgia. 1983;3:207–12.PubMedCrossRef
134.
Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16:257–63.PubMedCrossRef
135.
Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine–a double-blind placebo-controlled study. Cephalalgia. 1996;16:436–40.PubMedCrossRef
136.
Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–80.PubMedCrossRef
137.
Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. 2003;8:428–32.PubMed
138.
Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9:247–53.PubMed
139.
Boisen E, Deth S, Hübbe P, Jansen J, Klee A, Leunbach G. Clonidine in the prophylaxis of migraine. Acta Neurologica Scandinavica. 1978;58(5):288–95.PubMedCrossRef
140.
Adam EI, Gore SM, Price WH. Double blind trial of clonidine in the treatment of migraine in a general practice. J R Coll Gen Pract. 1978;28:587–90.PubMed
141.
Couch JR. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache. 2011;51:33–51.PubMedCrossRef
142.
Orholm M, Honore PF, Zeeberg I. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine. Acta Neurol Scand. 1986;74:235–9.PubMedCrossRef
143.
Orholm M, Le Fevre P. Prophylactic treatment of migraine with femoxetine—a randomized comparison with placebo. Cephalalgia 1985:516–7.
144.
Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17:109–12.PubMedCrossRef
145.
Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992;12:81–4.PubMedCrossRef
146.
Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994;44:647–51.PubMedCrossRef
147.
Welch KMA, Ellis DJ, Keenan PA. Successful migraine prohpylaxis with naproxen sodium. Neurology1985.
148.
Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Archives of neurology. 1985;42(6):582–4.PubMedCrossRef
149.
(MINES) M-NESG. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache. 1989;29:639–42.CrossRef
150.
Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009;31:542–59.PubMedCrossRef
151.
Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. Clin Neurol Neurosurg. 2008;110:979–84.PubMedCrossRef
Metadaten
Titel
Preventive Pharmacologic Treatments for Episodic Migraine in Adults
verfasst von
Tatyana A. Shamliyan, MD, MS
Jae-Young Choi, PhD
Rema Ramakrishnan, MPH
Jennifer Biggs Miller, PT, MPH
Shi-Yi Wang, MD, PhD
Frederick R. Taylor, MD
Robert L. Kane, MD
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 9/2013
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-013-2433-1

Weitere Artikel der Ausgabe 9/2013

Journal of General Internal Medicine 9/2013 Zur Ausgabe

Original Research

Prevalence and Predictors of Underinsurance Among Low-Income Adults

Capsule Commentary

Capsule Commentary on Bauer et al., Health Literacy and Antidepressant Adherence Among Adults with Diabetes: Implications for Future Research

Capsule Commentary

Capsule Commentary on Zafar et al., Predictor of CT Colonography Utilization Among Asymptomatic Medicare Beneficiaries

Letters

Bedside Rounding Strategies Used by Bedside Teachers

Editorials

Migraine Prophylaxis: Which Drugs Work and Which Ones Don’t

Letters

Statin Use and Osteoarthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise